Resources

February 16, 2021

Recapitulating the Multifaceted Inflammatory Environment of the Intestine In Vitro

Intestinal inflammatory diseases are highly complex, which has thus far prevented development of an effective in vitro disease model. With access to a donor-derived cell biobank and the ability to recapitulate region-specific environments of the intestine, Altis Biosystems is working toward the development of an in vitro RepliGut® model to accurately recapitulate the complex intestinal inflammatory microenvironments.

December 23, 2020

How Does Altis Biosystems Envision the Future of the Pharma/Biopharma Industry?

There is a growing need to address the high failure rate of drug candidates as they progress through clinical trials. Altis Biosystems aims to bring its technological advances to the forefront, enabling the drug development process to more effectively translate results from preclinical experiments to late-stage clinical trials.

November 30, 2020

Enhancing Human Gut Tissue Models through Gene Editing

The variety of normal and diseased human tissues needed to perform comprehensive screening of drug candidates is a key resource for next-generation preclinical models, but obtaining these tissues is challenging. Gene editing enables Altis Biosystems to offer a diverse array of RepliGut® human gut models tailored for specific research programs.

November 20, 2020

A Gut Feeling About the Future of Healthcare

Scott Magness, Chief Scientific Officer at Altis Biosystems, discusses the impact that RepliGut®—a human stem cell-derived platform that recreates the intestinal epithelium—may have on stem cell research and drug testing.

November 10, 2020

Increasing the Efficiency of Drug Development With Preclinical Testing Using Human Intestinal Stem Cells

Due to a lack of robust in vivo gut models, animal studies are generally required to evaluate gut toxicity. However, these studies can be lengthy and expensive and may not accurately recapitulate the behavior of the human gastrointestinal tract. Drugs are thus often developed with undesired gut side effects that are not apparent until clinical trials.